Ignite Creation Date:
2024-05-06 @ 5:41 PM
Last Modification Date:
2024-10-26 @ 2:33 PM
Study NCT ID:
NCT05395702
Status:
COMPLETED
Last Update Posted:
2022-05-27
First Post:
2022-05-19
Brief Title:
Study of Ingarons Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
Sponsor:
SPP Pharmaclon Ltd
Organization:
SPP Pharmaclon Ltd
Study Overview
Official Title:
Pilot Single-center Open Study of the Effect of Ingaron on the Efficacy and Resistance to Antibiotics in Antibacterial Therapy in Patients With Community-acquired Pneumonia
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to effect of Ingaron a lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100000 IU LLC NPP Farmaklon Russia on the effectiveness of antibiotic therapy in patients with community-acquired pneumonia who fell ill during the epidemiological rise of ARVI
Detailed Description:
Pilot open single-centre randomized controlled trial Patients will be prescribed basic combination antibiotic therapy In addition to antibiotic therapy half of the patients will receive Ingaron a lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration of 100000 IU LLC NPP Farmaklon Russia The study drug solution Ingaron will be administered intramuscularly at 100000 IU once daily for 5 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None